Literature DB >> 24215262

Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence.

Richard L Bell1, Marcelo F Lopez, Changhai Cui, Mark Egli, Kirk W Johnson, Kelle M Franklin, Howard C Becker.   

Abstract

Neuroinflammatory signaling pathways in the central nervous system are of current interest as potential pharmacotherapy targets for alcohol dependence. In this study, we examined the ability of ibudilast, a non-selective phosphodiesterase inhibitor, to reduce alcohol drinking and relapse in alcohol-preferring P rats, high-alcohol drinking HAD1 rats, and in mice made dependent on alcohol through cycles of alcohol vapor exposure. When administered twice daily, ibudilast reduced alcohol drinking in rats by approximately 50% and reduced drinking by alcohol-dependent mice at doses which had no effect in non-dependent mice. These findings support the viability of ibudilast as a possible treatment for alcohol dependence.
© 2013 Society for the Study of Addiction.

Entities:  

Keywords:  AV-411; Alcohol; MN-166; alcohol dependence; alcohol preference; alcoholism; ethanol; ibudilast; neuroimmune; phosphodiesterase

Mesh:

Substances:

Year:  2013        PMID: 24215262      PMCID: PMC4017009          DOI: 10.1111/adb.12106

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  20 in total

Review 1.  Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?

Authors:  Mark Egli
Journal:  Addict Biol       Date:  2005-12       Impact factor: 4.280

2.  The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family.

Authors:  Lucien C D Gibson; Stuart F Hastings; Ian McPhee; Robert A Clayton; Claire E Darroch; Alison Mackenzie; Fiona L Mackenzie; Michiaki Nagasawa; Patricia A Stevens; Simon J Mackenzie
Journal:  Eur J Pharmacol       Date:  2006-03-13       Impact factor: 4.432

Review 3.  Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease.

Authors:  P Rolan; Mr Hutchinson; Kw Johnson
Journal:  Expert Opin Pharmacother       Date:  2009-12       Impact factor: 3.889

4.  Increased ethanol drinking after repeated chronic ethanol exposure and withdrawal experience in C57BL/6 mice.

Authors:  Howard C Becker; Marcelo F Lopez
Journal:  Alcohol Clin Exp Res       Date:  2004-12       Impact factor: 3.455

5.  Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol.

Authors:  Roberto Rimondini; Christina Arlinde; Wolfgang Sommer; Markus Heilig
Journal:  FASEB J       Date:  2002-01       Impact factor: 5.191

6.  High mobility group box 1/Toll-like receptor danger signaling increases brain neuroimmune activation in alcohol dependence.

Authors:  Fulton T Crews; Liya Qin; Donna Sheedy; Ryan P Vetreno; Jian Zou
Journal:  Biol Psychiatry       Date:  2012-12-01       Impact factor: 13.382

Review 7.  Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes.

Authors:  Annemarie Ledeboer; Mark R Hutchinson; Linda R Watkins; Kirk W Johnson
Journal:  Expert Opin Investig Drugs       Date:  2007-07       Impact factor: 6.206

8.  Repeated cycles of chronic intermittent ethanol exposure in mice increases voluntary ethanol drinking and ethanol concentrations in the nucleus accumbens.

Authors:  William C Griffin; Marcelo F Lopez; Amy B Yanke; Lawrence D Middaugh; Howard C Becker
Journal:  Psychopharmacology (Berl)       Date:  2008-09-13       Impact factor: 4.530

9.  Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat.

Authors:  Hideaki Wakita; Hidekazu Tomimoto; Ichiro Akiguchi; Jin Xi Lin; Masafumi Ihara; Ryo Ohtani; Masunari Shibata
Journal:  Brain Res       Date:  2003-11-28       Impact factor: 3.252

10.  Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses.

Authors:  Paul Rolan; Jacqueline A Gibbons; Lin He; Eppie Chang; Drew Jones; Matthew I Gross; Jennifer Bahr Davidson; Laura M Sanftner; Kirk W Johnson
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

View more
  68 in total

Review 1.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

Review 2.  The role of neuroimmune signaling in alcoholism.

Authors:  Fulton T Crews; Colleen J Lawrimore; T Jordan Walter; Leon G Coleman
Journal:  Neuropharmacology       Date:  2017-02-01       Impact factor: 5.250

Review 3.  Low Vs. High Alcohol: Central Benefits Vs. Detriments.

Authors:  Yousef Tizabi; Bruk Getachew; Clifford L Ferguson; Antonei B Csoka; Karl M Thompson; Alejandra Gomez-Paz; Jana Ruda-Kucerova; Robert E Taylor
Journal:  Neurotox Res       Date:  2018-01-04       Impact factor: 3.911

Review 4.  An Animal Model of Alcohol Dependence to Screen Medications for Treating Alcoholism.

Authors:  H C Becker; M F Lopez
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

5.  The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.

Authors:  Xin Liu; Pi-Da Hao; Ming-Feng Yang; Jing-Yi Sun; Lei-Lei Mao; Cun-Dong Fan; Zong-Yong Zhang; Da-Wei Li; Xiao-Yi Yang; Bao-Liang Sun; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2017-05-06       Impact factor: 4.530

Review 6.  Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review.

Authors:  Eric A Woodcock; Ansel T Hillmer; Graeme F Mason; Kelly P Cosgrove
Journal:  Mol Neuropsychiatry       Date:  2019-05-09

Review 7.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 8.  The neuroimmune transcriptome and alcohol dependence: potential for targeted therapies.

Authors:  Anna Warden; Emma Erickson; Gizelle Robinson; R Adron Harris; R Dayne Mayfield
Journal:  Pharmacogenomics       Date:  2016-12-05       Impact factor: 2.533

9.  Tigecycline Reduces Ethanol Intake in Dependent and Nondependent Male and Female C57BL/6J Mice.

Authors:  Susan E Bergeson; Michelle A Nipper; Jeremiah Jensen; Melinda L Helms; Deborah A Finn
Journal:  Alcohol Clin Exp Res       Date:  2016-11-14       Impact factor: 3.455

Review 10.  Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies.

Authors:  Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis
Journal:  Pharmacol Biochem Behav       Date:  2019-01-26       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.